Research from the lab of MBI Director Dr. Jennifer Bizon and Dr. Barry Setlow was recently featured in The Washington Post. In the article, postdoctoral researcher Dr. Zak Krumm discusses animal studies exploring how GLP-1 drugs may influence dopamine signaling and the brain’s reward system.
The findings suggest these medications may alter how the brain processes reward – either by dampening dopamine responses or helping the brain reach a sense of satisfaction more quickly – which could reduce motivation or cravings. Researchers emphasize that this work is ongoing, and further studies are needed to better understand these effects in humans.
Read the article from The Washington Post.